Clinical Trial and Regulatory Approval Risk: The success of Aspire Biopharma Holdings, Inc. depends heavily on the successful completion of clinical trials and obtaining regulatory approvals for its investigational product, Multikine. Failure at any stage of these processes could significantly delay or prevent commercialization, adversely impacting the company's prospects.

Funding and Capital Needs Risk: Aspire Biopharma Holdings, Inc. has a history of losses and requires substantial additional funding to continue its research and development activities, fund clinical trials, and eventually commercialize any approved products. Inability to raise sufficient capital on favorable terms could lead to delays, curtailment of operations, or even the inability to continue as a going concern.

Intense Competition Risk: The biotechnology and pharmaceutical industries, particularly in oncology, are highly competitive. Aspire Biopharma Holdings, Inc. faces competition from numerous established companies with greater financial, technical, and human resources. Competitors may develop more effective or less costly treatments, or bring products to market sooner, reducing the potential market share or profitability of ASBP's products.